Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C]SHR1459 in Healthy Males
NCT05095337Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Jun 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of edralbrutinib in B cell malignancies and primary membranous nephropathy (PMN), sponsored by Hengrui. Primary endpoints: Time to Maximum Plasma Concentration, Maximum Plasma Concentration and 8 more. Status: unknown.
02
Drugs
edralbrutinib
03
Conditions
B cell malignanciesprimary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05095337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095337.